I can't think of a more fitting image for this post than to show how Berkshire Hathaway (BRK) has performed relative to the S&P500 (with dividends included) in just under 60 years. For several years I have trusted BRK in times of uncertainty. Now that I am helping a couple of young investors with minimal [...]
I consider Genuine Parts' (GPC) valuation to be compelling. This is a very different conclusion than that reached when I last reviewed it in this December 3 2022 post. 2023 Investor Day On March 23, GPC held its 2023 Investor Day in which it provided a strategic update on its key growth initiatives and outline [...]
In January, my Scotiabank (BNS) Is A Terrible Long-Term Investment guest post was published at Dividend Power. My recent TD Bank (TD) guest post is now accessible at Dividend Power. In my opinion, TD is far more appealing than BNS from a total long-term investment return perspective. Furthermore, I deem TD's credit risk to be [...]
A good time to initiate a BlackRock, Inc. (BLK) position would have been in late September/early October. However, due to an unexpected opportunity disclosed in my FFJ Portfolio – September 2022 Report, I regretfully had to remain on the sidelines. By the time my liquidity had improved, BLK's share price had rocketed higher and its [...]
In my A Look At Dividend Champion Jack Henry & Associates post at Dividend Power, I note that although JKHY's share price has retraced to the mid $160s from its ~$213 intra-day high set in early July 2022, the share price decline is no justification to acquire shares. A company's share price is merely what [...]
On February 21, Home Depot (HD) released Q4 and FY2022 results (January 29, 2023 FYE) and FY2023 guidance. Management expects 2023 to be a year of moderation and is targeting approximately flat comp sales and a mid-single-digit percent decline in diluted EPS compared to the prior fiscal year. This guidance has not been well received [...]
Fortunately for Rollins (ROL), pests are indifferent to economic conditions. It generates ~80% recurring revenue and boats 20+ years of revenue growth. I last reviewed this holding in my November 19, 2022 post. With the release of FY2022 results following the February 15 market close, I revisit it to determine whether I should acquire additional [...]
How times have changed after my November 25, 2022, Buy Out Of Favour West Pharmaceutical post! In that post, I noted that West Pharmaceutical's (WST) short-term headwinds had led to its valuation retracing to a reasonable level and that I had initiated a 100-share position @ ~$225/share in one of the 'Core' accounts within the [...]
I last reviewed S&P Global (SPGI) in my October 31, 2022 post at which time I considered shares to be attractively valued. It continues to have an attractive long-term outlook despite short-term Ratings Division headwinds. However, shares are not attractively valued. I like to accumulate shares in great companies when they experience short-term headwinds; SPGI [...]
I would have preferred to wait for the release of Stryker's (SYK) FY2022 Form 10-K. However, I have sufficient information in its January 31, 2023 Q4 2022 Form 8-K and the Form 10-Ks from prior years by which to make an investment decision. In this post, I point out several observations that convinced me SYK [...]
